Bank of Montreal Can lifted its holdings in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 7.3% during the second quarter, HoldingsChannel.com reports. The firm owned 18,950 shares of the company’s stock after acquiring an additional 1,288 shares during the quarter. Bank of Montreal Can’s holdings in Ionis Pharmaceuticals were worth $789,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Motley Fool Asset Management LLC raised its position in shares of Ionis Pharmaceuticals by 9.6% during the first quarter. Motley Fool Asset Management LLC now owns 284,100 shares of the company’s stock worth $12,523,000 after purchasing an additional 25,000 shares during the period. Eaton Vance Management acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth about $353,000. Employees Retirement System of Texas raised its position in shares of Ionis Pharmaceuticals by 110.7% during the first quarter. Employees Retirement System of Texas now owns 59,000 shares of the company’s stock worth $2,601,000 after purchasing an additional 31,000 shares during the period. Lyon Street Capital LLC acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth about $3,066,000. Finally, Swiss National Bank raised its position in shares of Ionis Pharmaceuticals by 2.3% during the first quarter. Swiss National Bank now owns 216,700 shares of the company’s stock worth $9,552,000 after purchasing an additional 4,900 shares during the period. 94.19% of the stock is currently owned by institutional investors.

NASDAQ:IONS opened at $51.67 on Tuesday. The company has a quick ratio of 8.34, a current ratio of 8.38 and a debt-to-equity ratio of 0.76. The stock has a market cap of $6.69 billion, a P/E ratio of 636.88 and a beta of 2.66. Ionis Pharmaceuticals Inc has a 52-week low of $39.07 and a 52-week high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.20). The firm had revenue of $117.75 million for the quarter, compared to the consensus estimate of $128.22 million. Ionis Pharmaceuticals had a negative return on equity of 1.22% and a negative net margin of 7.20%. research analysts predict that Ionis Pharmaceuticals Inc will post -0.31 earnings per share for the current year.

IONS has been the topic of a number of research analyst reports. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a research report on Wednesday, May 9th. Morgan Stanley decreased their price objective on Ionis Pharmaceuticals to $52.00 and set an “equal weight” rating for the company in a report on Monday, May 7th. Stifel Nicolaus decreased their price objective on Ionis Pharmaceuticals to $57.00 and set a “hold” rating for the company in a report on Monday, May 7th. ValuEngine downgraded Ionis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 8th. Finally, Barclays downgraded Ionis Pharmaceuticals from an “equal weight” rating to an “underweight” rating and set a $52.00 price objective for the company. in a report on Wednesday, June 20th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $52.78.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $45.00, for a total value of $562,500.00. Following the completion of the transaction, the senior vice president now directly owns 19,409 shares in the company, valued at $873,405. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Spencer R. Berthelsen sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $42.30, for a total value of $634,500.00. Following the completion of the transaction, the director now owns 97,127 shares of the company’s stock, valued at $4,108,472.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,656 shares of company stock valued at $1,901,087. 2.44% of the stock is owned by corporate insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Recommended Story: Stock Symbol

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.